Early in the morning on Friday, the Senate voted along party lines (52-47) to confirm US Rep. Tom Price, R-Georgia, as secretary of HHS. President Donald Trump nominated Price with the expectation that he will lead the charge to repeal and replace the Affordable Care Act.
Early in the morning on Friday, the Senate voted along party lines (52-47) to confirm US Rep. Tom Price, R-Georgia, as secretary of HHS. President Donald Trump nominated Price with the expectation that he will lead the charge to repeal and replace the Affordable Care Act (ACA).
In the past, Price has proposed legislation for replacing the ACA, in addition he supports a plan to turn the Medicare program into a voucher program.
“He can start having a positive impact almost as soon as he’s confirmed,” US Senate Majority Leader Mitch McConnell, R-Kentucky, said in remarks on the Senate floor when discussing the need to confirm Price. “He can start bringing stability to the healthcare markets Obamacare has harmed. He can start bringing relief to the families Obamacare has hurt. I know he’s ready to get to work with Congress to move toward truly patient-centered health care, care that prioritizes the needs of patients over the needs of Washington."
As head of HHS, Price will oversee agencies responsible for regulating food and drugs, combating public health crises, and sponsoring research.
The confirmation process for Price was contentious. Democrats were accused of “dragging their feet” as they sought to address concerns that Price would pare down insurance protections and health programs, in addition to ethics questions over stock trades.
During a speech on the Senate floor, Senator Elizabeth Warren, D-Massachusetts, attempted to sway Republicans to join the Democrats in voting against Price. She separated out Price from Trump’s nominees to other Cabinet positions, noting that while those other nominees were usually unqualified for the positions they were picked, Price “has a lot of experience in healthcare policy.”
However, Warren made it clear that it is not experience she agrees with.
“Yes he has experience; but it is the kind of experience that should horrify you if you care about Medicare, if you care about Medicaid, or if you care about your own insurance coverage,” Warren said. “Congressman Price’s record is perfectly clear: he wants to destroy fundamental protections that millions of Americans depend on for their health and their economic security.”
House Speaker Paul Ryan, R-Wisconsin, called the confirmation a “big step forward” for Americans who are struggling under the ACA.
“As we have made clear, the time for patient-centered reform is now, and Tom is–without question–the leader at HHS we need to make it happen,” Ryan said. “We look forward to working with him to expand access to quality, affordable health care.”
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Real-World Study Reveals Key Insights Into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More